Abstract Number: 0596 • ACR Convergence 2025
Effect of Gender and Follow-up Time in Damage Accrual: Data from a Latin America Lupus Cohort
Background/Purpose: Previous studies have shown that male gender is an independent predictor of organ damage in patients with systemic lupus erythematosus (SLE), particularly in the…Abstract Number: 0567 • ACR Convergence 2025
Sonelokimab in Biologic-Experienced Patients With Active Psoriatic Arthritis: Results From a Phase 2 Trial (ARGO) and Study Design of a Phase 3 Trial (IZAR-2) in Patients With Inadequate Response or Intolerance to Biologic TNFi, Including a Risankizumab Reference Arm
Background/Purpose: Sonelokimab (SLK), a novel Nanobody that binds to both IL-17A and IL-17F with similarly high affinity, is designed to target difficult-to-reach sites of inflammation.…Abstract Number: 0126 • ACR Convergence 2025
Performance of the 2023 and 2006 APS Classification Criteria in Pediatric Patients Diagnosed with APS: A Multisite Cohort Study
Background/Purpose: Antiphospholipid syndrome (APS) is a thrombo-inflammatory disorder that causes significant morbidity and mortality, even in children. The 2023 ACR/EULAR classification criteria, which use weighted…Abstract Number: 2616 • ACR Convergence 2025
Real-World Implication of Clinical Disease Activity Index (CDAI) Utilization on Treatment Decisions and Clinical Outcomes in Rheumatoid Arthritis
Background/Purpose: The University of North Carolina (UNC) Hospitals Rheumatology Clinic is utilizing the Clinical Disease Activity Index (CDAI) in patients with rheumatoid arthritis (RA) per…Abstract Number: 2370 • ACR Convergence 2025
Comparative Efficacy and Safety of IL-17 Inhibitors Versus Adalimumab in Biologic-Naive Psoriatic Arthritis Patients: A Meta-Analysis of Randomized Controlled Trials
Background/Purpose: Psoriatic arthritis (PsA) is a chronic immune-mediated disease which involves joints, skin, and nails, leading to deformities, decreased function, lower quality of life, and…Abstract Number: 2357 • ACR Convergence 2025
Impact of Sonelokimab, a Novel IL-17A- and IL-17F-Inhibiting Nanobody, in Active Psoriatic Arthritis: Key Subgroup Analyses in the Randomized, Double-Blind, Placebo-Controlled Phase 2 ARGO Trial
Background/Purpose: PsA is a chronic inflammatory disease affecting heterogeneous tissues, with unmet need for therapies with robust efficacy across disease domains. Sonelokimab (SLK) is a…Abstract Number: 1455 • ACR Convergence 2025
Sonelokimab in Patients With Active Psoriatic Arthritis Who Are Naive to Biologic DMARDs: Phase 2 ARGO Analysis and Phase 3 IZAR-1 Study Design
Background/Purpose: Sonelokimab (SLK), a novel Nanobody that binds to both IL-17A and IL-17F with similarly high affinity, is designed to target difficult-to-reach sites of inflammation…Abstract Number: 1347 • ACR Convergence 2025
The Better Disease-modifying antirheumatic drug (DMARD)? Efficacy and Safety of Methotrexate Versus Leflunomide Monotherapy in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
Background/Purpose: Methotrexate (MTX) and leflunomide (LEF) are commonly used disease-modifying antirheumatic drugs (DMARDs) in the treatment of rheumatoid arthritis (RA). While both are widely prescribed,…Abstract Number: 1286 • ACR Convergence 2025
Response to Hydroxychloroquine in Immune Thrombocytopenia in Childhood-Onset Systemic Lupus Erythematosus
Background/Purpose: The management of immune thrombocytopenia in childhood-onset systemic lupus erythematosus (cSLE) is not standardized. We examined the efficacy and safety of hydroxychloroquine (HCQ) as…Abstract Number: 0106 • ACR Convergence 2024
IgM and IgG Phosphatidylserine Antibody Detection May Improve Classification Accuracy of SLE and APS
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune coagulopathy that causes microvascular and macrovascular thrombosis in both venous and arterial systems. This can occur as a…Abstract Number: 0116 • ACR Convergence 2024
Assessment of Triple Antiphospholipid Antibody-positive Patients Based on Clinical and Laboratory Domains of 2023 ACR/EULAR Antiphospholipid Syndrome Classification Criteria
Background/Purpose: Triple aPL-positive (lupus anticoagulant test [LA], anticardiolipin antibody (aCL), and anti-β2 glycoprotein-I antibody [aβ2GPI]) patients are at higher risk to develop a severe clinical…Abstract Number: 0510 • ACR Convergence 2024
Applying Machine Learning Tools for Personalized Healthcare: Predicting Responses to Biologics in Rheumatoid Patients Through Comorbidity and Blood Test Analysis
Background/Purpose: This study aims to employ various machine learning tools to predict the responses of rheumatoid arthritis (RA) patients to biologic treatments, using data from…Abstract Number: 0772 • ACR Convergence 2024
Global Recruiting Patterns Are Associated with Placebo Response Rates in Clinical Trials of Psoriatic Arthritis
Background/Purpose: Therapeutic advances of the recent past have led to significant changes in clinical practice when treating patients with psoriatic arthritis (PsA). Since the advent…Abstract Number: 0775 • ACR Convergence 2024
A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab in IgG4-Related Disease (MITIGATE): Primary Efficacy and Safety Findings
Background/Purpose: IgG4-related disease (IgG4-RD) is a rare, systemic, fibroinflammatory disease characterized by unpredictable and recurring flares, leading to organ damage and decreased quality of life.…Abstract Number: 0850 • ACR Convergence 2024
Assessment of Correlation Between Composite Ultrasonographic Index (ECODAS) and Disease Activity Score 28 in Patients with Rheumatoid Arthritis
Background/Purpose: Conventional Disease Activity Score 28 has variable sensitivity, subjectivity, inherent bias due to certain variables such as more weightage to joint tenderness and overestimation…
- 1
- 2
- 3
- 4
- Next Page »